438 results about "Tumor angiogenesis" patented technology

An apparatus, system, method, and computer readable medium containing computer-executable code for implementing image analysis uses multivariate statistical analysis of sample images, and allows segmentation of the image into different groups or classes, depending on a correlation to one or more sample textures, or sample surface features. In one embodiment, the invention performs multivariate statistical analysis of ultrasound images, wherein a tumor may be characterized by segmenting viable tissue from necrotic tissue, allowing for more detailed in vivo analysis of tumor growth beyond simple dimensional measurements or univariate statistical analysis. Application of the apparatus and method may also be used for characterizing other types of samples having textured features including, for example, tumor angiogenesis biomarkers from Power Doppler.

The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked beta2-Glycoprotein 1 (beta2GP1) to cells associated with the tissue. The presence of beta2GP1 inhibits angiogenesis within the tissue, in part by preventing neovascularization into the tissue. The disclosure also provides a method for treating tumors by providing beta2GP1 to the tumor.

The present invention provides cloned, genetically modified, endothelial cells, and the stem cells from which they are derived, which are produced by somatic cell nuclear transfer. The invention further provide novel therapeutic methods in which such cells are administered to a patient with tumors to inhibit and / or disrupt angiogenesis of the tumors, thereby inhibiting tumor growth and killing tumor cells.

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and / or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

The invention relates to the field of medicaments, in particular to an integrin blocking agent HM-3 which has the function of inhibiting tumor angiogenesis, integrin affinity and a bonding capacity and application thereof. The blocking agent is a polypeptide modified with polyethylene glycol, and the modified integrin blocking agent polypeptide can be applied to treatment of solid tumors. During application of the integrin blocking agent to preparation of a tumor treatment medicament, the sequence and structure of the integrin blocking agent is mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. The integrin blocking agent polypeptide designed in the invention is scientific, reasonable, practical and effective, can be used for preparing a treatment medicament for treating human solid tumors, and has remarkable social value and market value; and the treatment spectrum of the integrin blocking agent is expanded greatly, and novel thought and prospect are provided for future development of medicaments.

The invention discloses application of active ingredients of juncus effuses in the preparation of medicaments for resisting tumors or inhibiting angiogenesis, health-care food or cosmetics. In the invention, the active ingredients of juncus effuses has the activity of inhibiting the tumors and tumor angiogenesis, and the prepared medicaments for inhibiting the tumors and the tumor angiogenesis can be used for treating or preventing malignancy and diseases relevant to the tumor angiogenesis and also can be used for treatment in tumor chemotherapy and / or auxiliary chemotherapy. In the application, the medicinal curative effect and effect mechanism of the active ingredients of juncus effuses are studied and clarified by taking tumor stem cells, tumor cells and tumor neoangiogenesis as targetspots for treating diseases so as to establish a foundation for the research and development of the active ingredients of juncus effuses and the innovative anti-tumor traditional Chinese medicines ofthe active ingredients and provide scientific basis and important information for the Chinese medicinal treatment of the malignancy.

The invention relates to a method for preparing isoflavone metal complexes shown as formulas I and II, and application of the isoflavone metal complexes. The definition of each group is shown in the description. The compounds and pharmaceutically acceptable salts thereof or hydrates thereof or solvate medicinal compositions thereof can be used for treating tumors and tumor angiogenesis or tumor metastasis medicaments. The structural formulas are shown in the attached figure 1 of the abstract.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

A magnetic resonance imaging (MRI) methodology is provided for simultaneous measurement of dynamic susceptibility contrast (DSC) MRI and dynamic contrast enhanced (DCE) MRI perfusion and permeability parameters using a combination of dual echo and spiral acquisition techniques with no contrast agent preload. T1 and T2 / T2* leakage effects are eliminated, thereby permitting accurate measurement of blood volume, blood flow and vascular permeability which are used in evaluating tumor angiogenesis.

The present invention provides antibodies specifically against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies), a fragments of the antibodies, hybridomas that produce the antibodies, a complex of the antibody or antibody fragment and an agent, a pharmaceutical composition comprising the antibody and the like, a tumor therapeutic agent, a tumor angiogenesis inhibitor, a tumor diagnostic agent, a method for detecting tumor, a kit for detecting and / or diagnosing tumor, etc.

The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

An apparatus, system, method, and computer readable medium containing computer-executable code for implementing image analysis uses multivariate statistical analysis of sample images, and allows segmentation of the image into different groups or classes, depending on a correlation to one or more sample textures, or sample surface features. In one embodiment, the invention performs multivariate statistical analysis of ultrasound images, wherein a tumor may be characterized by segmenting viable tissue from necrotic tissue, allowing for more detailed in vivo analysis of tumor growth beyond simple dimensional measurements or univariate statistical analysis. Application of the apparatus and method may also be used for characterizing other types of samples having textured features including, for example, tumor angiogenesis biomarkers from Power Doppler.

The invention belongs to the field of chemical drugs, and discloses a ruthenium complex capable of inhibiting tumor angiogenesis and a preparation method and application thereof. The ruthenium complex provided by the invention has a structure shown in a formula I or II. The preparation method comprises the following steps of: dropwise adding a silver nitrate solution to a sodium salt solution, stirring and reacting, then filtering, washing and vacuum drying a precipitate, and thereby obtaining a ligand O-O; taking ruthenium chloride, L, and lithium chloride to be dissolved in N-, N-dimethyl formamide, heating and refluxing under the protection of argon atmosphere to obtain an intermeidate Ru (L2) Cl22 +; allowing the ligand O-O and the Ru (L2) Cl22 + to be dissolved in an ethanol / water mixed solvent, heating and refluxing to obtain the ruthenium complex shown in the formula I; and allowing the Ru (L2) Cl22 +, 8- hydroxyquinoline, and ammonium acetate to be dissolved in ethanol, and heating and refluxing under the protection of argon atmosphere to obtain the ruthenium complex shown in the formula II. The ruthenium complex has the advantages of good stability, uneasiness in hydrolysis, good solubility, low toxicity, and the ability to inhibit tumor angiogenesis, and is easily absorbed by the human body.

Provided herein are methods for inhibiting tumor angiogenesis in a cancer patient, the method comprising administering to the subject an effective amount of a first isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF.

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, in duce cellular apoptosis and / or inhibit transcription in the subject.

The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.

The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and / or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acuds, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and / or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.

The present invention relates to a novel pharmaceutical composition of benproperine derivatives for preventing and treating angiogenesis-related diseases. The benproperine derivatives and pharmaceutically acceptable salts thereof according to the present invention inhibit cancer cell migration and the angiogenesis of vascular endothelial cells, and therefore can be effectively used not only as an anticancer agent, but also as an agent for preventing and treating diseases caused by abnormal angiogenesis, such as diabetic retinopathy and corneal transplant rejection.

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.

DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and / or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

The invention belongs to the technical field of genetically engineered antibody, in particular relates to a fusion protein of tumor vascular endothelial growth factor receptor 2 (VEGFR2 / KDR3) antibody and MICA as well as a preparation method and use thereof. In the invention, a full-length antibody of VEGFR2 is linked with a ligand MHC I molecule associated protein A (MICA) of activated receptor of NK cell (NKG2D) through a flexible linker and expressed by CHO cells by utilizing the genetic engineering technology, and the formed fusion protein can act on VEGFR on the surface of a tumor cell to inhibit or kill tumor and inhibit or destroy tumor angiogenesis, and on the other hand, the formed fusion protein can increase the level of MICA on the surface of the tumor cell and stimulate the NK cells to kill tumor cells through identification of NKG2D on the surfaces of the NK cells, thereby reestablishing the immunological surveillance of an body activated by the NKG2D pathway, and enhancing effects of antibody-dependent cell-mediated cytotoxicity (ADCC) and the like mediated by the Fc region of the antibody to kill tumor cells.

Cholesterol-uptake-blocking drugs inhibit angiogenesis and are useful to inhibit diseases perpetuated by angiogenesis. Cholesterol reduction with the use of the drugs increases the intratumoral level of thrombospondin-1, an angiogenesis inhibitor. Ezetimibe (Zetia®), a specific cholesterol-uptake blocking drug, also retards the growth of human tumors, most preferably in combination with low-cholesterol diet. The pharmacologic reduction in serum cholesterol retards prostate cancer growth by inhibiting tumor angiogenesis to combat the growth of prostatic tumors which are directly accelerated by hypercholesterolemia.

The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject. (I)

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

The invention relates to an anti-tumor drug compound and application thereof. The compound includes a glutaminase inhibitor and a tumor angiogenesis inhibitor which are used together with each other. The invention especially provides the glutaminase inhibitor as shown as formula (I) listed in a specification. The glutaminase inhibitor has an obvious inhibiting effect for glutaminase activity. The inhibition for the growth of the tumor strain can reach up to 90% or above under the condition that the dosage of the drug combination is only 1 / 5 of the dosage of singly used drugs, the generation of the bloods surrounding human tumors and the transfer of the tumors are obviously restrained and the corresponding side effect of the drug combination is much lower than that of single drug, so that the drug combination of the glutaminase inhibitor and the tumor angiogenesis inhibitor at a certain ratio is effective in treating tumors and the drug combination compared with the single drug has an obvious synergic effect and is an efficient low-toxicity antitumor drug combination.

The invention discloses phenylpiperazine derivatives and pharmaceutically acceptable salts thereof. The invention is characterized in that: the derivatives have the structure shown as a formula I; and in the formula, R1 refers to -H, -R, -OR, -COOR, halogen or -CN group, R refers to alkyl, the substitution position of R1 on a benzene ring is a para-position, ortho-position or meta-position of piperazine, m is a natural number ranging from 0 to 2, and R2 refers to a substituted or unsubstituted carboxyl group or sulfonic acid group. The phenylpiperazine derivatives and pharmaceutically acceptable salts thereof can be prepared into medicines for inhibiting tumor cell metastasis and tumor angiogenesis, medicines for treating liver cancer, breast cancer, ovarian cancer, gastric cancer, colon cancer, lung cancer or melanoma, tumor chemotherapy medicines and auxiliary medicines in surgical therapy.